Please assess the completion status of the following clinical trial:

Trial Title: Phase 2b Study in NASH to Assess IVA337

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult subjects, age ≥18 years.~* NASH histological diagnosis according to the currently accepted definition of both EASL and AASLD, requiring the combined presence of steatosis (any degree ≥ 5%) + lobular inflammation of any degree + liver cell ballooning of any amount, on a liver biopsy performed ≤ 6 months before screening in the study or at screening and confirmed by central reading during the screening period and~  * SAF Activity score of 3 or 4 (\>2)~ * SAF Steatosis score ≥ 1~ * SAF Fibrosis score \< 4~* Subject agrees to have a liver biopsy performed after 24 weeks of treatment.~* Compensated liver disease~* No other causes of chronic liver disease (autoimmune, primary biliary cholangitis, Hepatitis B virus (HBV), hepatitis C virus (HCV), Wilson's, α-1-antitrypsin deficiency, hemochromatosis, etc...).~* If applicable, have a stable type 2 diabetes, defined as HbA1c ≤ 8.5% and fasting glycemia \<10 mmol/L, no changes in medication in the previous 6 months, and no new symptoms associated with decompensated diabetes in the previous 3 months.~* Have a stable weight since the liver biopsy was performed defined by no more than a 5 % loss of initial body weight.~* Negative pregnancy test or post-menopausal. Women with childbearing potential (i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile) must be using a highly effective method of contraception (i.e. combined (estrogen and progestogen containing) hormonal/ progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomised partner). The contraceptive method will have to be followed for at least one menstruation cycle after the end of the study~* Subjects having given her/his written informed consent.~Exclusion Criteria:~* Evidence of another form of liver disease.~* History of sustained excess alcohol ingestion: daily alcohol consumption \> 30 g/day (3 drinks per day) for males and \> 20 g/day (2 drinks per day) for females.~* Unstable metabolic condition: Weight change \> 5kg in the last three months, diabetes with poor glycemic control (HbA1c \> 8.5%), introduction of an antidiabetic or of an anti-obesity drug/malabsorptive or restrictive bariatric (weight loss) surgery in the past 6 months prior to screening.~* History of gastrointestinal malabsorptive bariatric surgery within less than 5 years or ingestion of drugs known to produce hepatic steatosis including corticosteroids, high-dose estrogens, methotrexate, tetracycline or amiodarone in the previous 6 months.~* Significant systemic or major illnesses other than liver disease, including congestive heart failure (class C and D of the American Heart Association , AHA), unstable coronary artery disease, cerebrovascular disease, pulmonary disease, renal failure, organ transplantation, serious psychiatric disease, malignancy that, in the opinion of the investigator, would preclude treatment with IVA337 and/or adequate follow up.~* HB antigen \>0, HCV Polymerase chain reaction (PCR) tests \>0 (patients with a history of HCV infection can be included if HCV PCR is negative since more than 3 years), HIV infection.~* Pregnancy/lactation or inability to adhere to adequate contraception in women of child-bearing potential.~* Active malignancy except cutaneous basocellular carcinoma.~* Any other condition which, in the opinion of the investigator would impede competence or compliance or possibly hinder completion of the study.~* Body mass index (BMI) \>45 kg/m2.~* Type 1 diabetes and type 2 diabetic patient on insulin.~* Diabetic ketoacidosis~* Fasting Triglycerides \> 300 mg/dL.~* Hemostasis disorders or current treatment with anticoagulants.~* Contra-indication to liver biopsy.~* History of, or current cardiac dysrhythmias and/or a history of cardiovascular disease event, including myocardial infarction, except patients with only well controlled hypertension. Any clinically significant ECG abnormality reported by central ECG reading.~* Participation in any other clinical study within the previous 3 months.~* Have a known hypersensitivity to any of the ingredients or excipients of the Investigational medicinal product (IMP)~* Be possibly dependent on the Investigator or the sponsor (e.g., including, but not limited to, affiliated employee).~* Creatine phosphokinase (CPK)\>5 x ULN~* Osteopenia or any other well documented Bone disease. Patient without well documented osteopenia treated with vitamin D and/or Calcium based supplements for preventive reasons can be included.~(The criteria below are applicable only for patients who will undergo a MRI/LMS in selected centers)~* Claustrophobia to a degree that prevents tolerance of MRI scanning procedure. Sedation is permitted at discretion of investigator.~* Metallic implant of any sort that prevents MRI examination including, but not limited to: aneurysm clips, metallic foreign body, vascular grafts or cardiac implants, neural stimulator, metallic contraceptive device, tattoo, body piercing that cannot be removed, cochlear implant; or any other contraindication to MRI examination.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IVA337 1200mg (Type: EXPERIMENTAL): IVA337 400mg, once a day (Quaque Die, QD) with food
- IVA337 800mg (Type: EXPERIMENTAL): IVA337 400mg, once a day (Quaque Die, QD) with food
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to match, once a day (Quaque Die, QD) with food

Based on this trial design, predict the completion outcome and termination type (if applicable).